KardioVis develops an end-to-end heart failure monitoring solution that uses non-invasive, AI-enhanced technology to capture subtle cardiac signals through a 10-second measurement over clothing, with no skin contact required. The platform aims to detect cardiac deterioration weeks before an acute event occurs, supporting proactive rather than reactive care. A clinical investigation authorized by the Italian Ministry of Health is underway with 120 patients at Modena University Hospital.
Funding
Funding not disclosed
Founders
Product
Problem
Heart failure develops silently with subtle physiological changes that remain unnoticed until symptoms appear. Today, detection is often reactive rather than proactive, leaving limited opportunity for early intervention and increasing the risk of acute events and hospitalizations.
Solution
KardioVis provides an end-to-end heart failure monitoring solution integrating a novel, non-invasive, AI-enhanced technology that captures subtle cardiac signals through a 10-second measurement over clothing, with no skin contact required. The system is designed for use anywhere, anytime, and by anyone, enabling patients to comfortably monitor their health at home while giving clinicians reliable, complete information to guide therapy plans. The final goal is to detect cardiac deterioration weeks before an acute event occurs, shifting from reactive to proactive heart failure management. The solution is currently undergoing clinical validation, with a first clinical study authorized by the Italian Ministry of Health involving 120 patients at Modena University Hospital.
Target Audience
Primary users are heart failure patients who need a comfortable, user-friendly device for at-home monitoring, and clinicians who need reliable, complete information to guide therapy plans and avoid acute events and hospitalizations.
Features
- Non-invasive cardiac signal capture in 10 seconds over clothing, requiring no skin contact
- AI-enhanced analysis of subtle cardiac signals to predict heart failure risk and detect deterioration weeks before acute events
- End-to-end monitoring platform designed for seamless integration into daily life and clinical workflows
- Clinical validation supported by data from 90+ individuals tested, 9000+ complete cardiac cycles measured, and zero faulty measurements observed during tests
- Partnership with Log80, a digital health and clinical data specialist, to support development and validation of the Digital Heart platform